Shiyao Group: Lenalidomide injection approved for clinical trials in China.

Shiyao Group announcement, the group's developed Luncakane monoclonal antibody injection has been approved by the China National Medical Products Administration and can be used in clinical trials in China, becoming the first domestically approved Luncakane monoclonal antibody injection biosimilar drug.